IONS vs PTCT โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
PTCT Captures Institutional Edge (3โ1 Pillars ยท 8โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to PTC Therapeutics, Inc. (PTCT) driven by superior Valuation, Growth & Margin, Momentum & Technical while IONS counters with relative strength in Options & Structure. Fundamentally, IONS trades at 90.9x Forward P/E with -58.8% operating margin (+54.9% YoY revenue) versus PTCT at 19.9x Forward P/E and 21.5% operating margin (+69.6% YoY). In options structure, IONS sits in BREAKDOWN (17th %ile IV; Dealer Gamma Walls on Pro) against PTCT sits in BREAKDOWN (17th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | IONS Revenue | PTCT Revenue | IONS Op. Margin | PTCT Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $600M | $260M | -10.2% | -43.7% | IONS |
| FY2019 | $1.12B | $310M | 32.6% | -78.6% | IONS |
| FY2020 | $730M | $380M | -23.6% | -113.4% | IONS |
| FY2021 | $810M | $540M | -3.7% | -69.5% | IONS |
| FY2022 | $590M | $700M | -69.8% | -64.0% | PTCT |
| FY2023 | $790M | $940M | -44.9% | -46.9% | IONS |
| FY2024 | $710M | $810M | -67.4% | -37.5% | PTCT |
| FY2025 | $940M | $1.73B | -40.4% | 50.1% | PTCT |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | IONS | PTCT | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $4.7B | $5.3B | Larger Scale | PTCT |
| Trailing P/E Ratio Valuation | 90.9x | 19.4x | Lower Multiple | PTCT |
| Forward P/E Ratio Valuation | 90.9x | 19.9x | Lower Multiple | PTCT |
| Revenue Growth (YoY) Growth | +54.9% | +69.6% | Higher Growth | PTCT |
| Operating Margin (TTM) Profitability | -58.8% | 21.5% | Higher Margin | PTCT |
| Net Profit Margin Profitability | -56.9% | -9.2% | Higher Margin | PTCT |
| Return on Equity (ROE) Capital Efficiency | -108.0% | -7740.1% | Higher ROE | IONS |
| 52-Week Range Position Momentum | 2% ($27โ$87) | 9% ($59โ$91) | Stronger Trend | PTCT |
| Beta / 30D Volatility Risk Regime | 0.18ฮฒ ยท 86% Vol | 0.81ฮฒ ยท 58% Vol | Lower Realized Risk | PTCT |
| Unified Institutional Score Composite Signal | 63.9 / 100 (BUY) | 45.4 / 100 (HOLD) | Higher Composite | IONS |